Table 2.
The impact of the pathologically and endoscopically measured lesion sizes on the surveillance intervals (based on the size cutoff of 1 cm)
| Adenoma*,# | Serrated polyps*,¶ | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| PMS<1 cm (n=221) | PMS≥1 cm (n=41) | Total (n=262) | PMS<1 cm (n=173) | PMS≥1 cm (n=16) | Total (n=189) | |
| EMS<1 cm, n (%) | 198 (96.6%) | 7 (3.4%) | 205 (100%) | 152 (97.4%) | 4 (2.6%) | 156 (100%) |
| EMS≥1 cm, n (%) | 23 (40.4%) | 34 (59.6%) | 57 (100%) | 21 (63.6%) | 12 (36.4%) | 33 (100%) |
PMS: pathologically measured size; EMS: endoscopically measured size; Serrated polyps include hyperplastic polyp, traditional serrated adenoma and sessile serrated adenoma;
*
a P value less than 0.001 in the χ2 tests;
#
ĸ=0.626 (95% confidence intervals [CI], 0.505 to 0.746);
¶
ĸ=0.424 (95% CI, 0.244 to 0.604).